Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T80452
(Former ID: TTDI01556)
|
|||||
Target Name |
Mucin (MUC)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Vitamin deficiency [ICD-11: 5B55-5B5F] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | KLS-0611 | Drug Info | Phase 2 | Xerophthalmia | [2] | |
Discontinued Drug(s) | [+] 1 Discontinued Drugs | + | ||||
1 | 15(S)-hydroxyeicosatetraenoic acid (ophthalmic, dry eye), Alcon | Drug Info | Discontinued in Phase 3 | Ocular disease | [3], [4] | |
Mode of Action | [+] 2 Modes of Action | + | ||||
Stimulator | [+] 1 Stimulator drugs | + | ||||
1 | KLS-0611 | Drug Info | [1] | |||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | 15(S)-hydroxyeicosatetraenoic acid (ophthalmic, dry eye), Alcon | Drug Info | [5] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | WO patent application no. 2011,1034,23, Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors. | |||||
REF 2 | ClinicalTrials.gov (NCT00721656) Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes. U.S. National Institutes of Health. | |||||
REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3401). | |||||
REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019901) | |||||
REF 5 | 15(S)-hydroxyeicosatetraenoic acid (15-HETE), a product of arachidonic acid peroxidation, is an active component of hemozoin toxicity to monocytes. Parassitologia. 1999 Sep;41(1-3):199-202. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.